A randomized, placebo-controlled, double-blind clinical trial is to evaluate the safety and immunogenicity of a new inactivated EV71 vaccine developed by Sinovac Biotech CO., LTD.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
540
inactivated vaccine (vero cell) against EV71 of 100U /0.5ml, two doses, 28 days interval
inactivated vaccine (vero cell) against EV71 of 200U /0.5ml, two doses, 28 days interval
inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
GuangXi Center for Diseases Control and Prevention
Nanning, Guangxi, China
Neutralization antibody geometric mean titer in infants 28 days after immunization with EV71 vaccine with or without aluminium hydroxide adjuvant
Primary immunogenicity end point were geometric mean titer of neutralization antibody againt EV71 virus \>= 1:8
Time frame: 6 month
The rates and severity of solicited adverse events in infants following immunization as a Measure of Safety and Tolerability
solicited local adverse events include Pain, Redness, Swelling, Induration, Rash, Pruritus at injection site. solicited general adverse events include Fever, Nausea, Vomiting, Diareahhea, Decreased appetite, Be agitated (irritability, abnormal crying), fatigue, allergy
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
inactivated vaccine (vero cell) against EV71 without adjuvant of 200U /0.5ml, two doses, 28 days interval
0.5ml placebo, two doses, 28 days interval